Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for Liver Fat in Obese Subjects
NCT03864783Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Curcumin with Placebo (2 arms). Primary endpoint: Curcumin's effect on steatosis at 42 days. Started Mar 2019; status: completed.
02
Drugs
curcumin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03864783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864783.